Brit. med. J., 1968, 4, 741-743 Summary: Azathioprine (Imuran) was administered to seven patients with ulcerative colitis suffering from a relapse which could not be controlled by adrenocortical steroids. In four patients remission started one to two weeks after initiation of antimetabolite therapy. Corticosteroid administration was continued concurrently with azathioprine, but the dosage could be reduced and in one case they were withdrawn.
Apart from transient leucopenia in two cases, and transient nausea and vomiting in two, no complications were encountered.
Antimetabolites have been used in the treatment of ulcerative colitis with success (Bean, 1966a , Bowen et al., 1966 Mackay et al., 1966; Swanson and Schwartz, 1967) . Some authors (Avery Jones et al., 1966; Bowen et al., 1966; Mackay et al., 1966) encountered toxic side-effects, including severe leucopenia and alopecia, but large doses were given to some of their patients (6 mg./kg./day of azathioprine (Imuran) (Bowen et al., 1966) , 600 mg./day (Mackay et al., 1966) 3 mg./kg./day, while prednisone was continued. There was a slight decrease in the number of stools and the amount of blood passed. However, he continued to lose weight and developed progressive iron-deficiency anaemia. After two months in hospital he began to gain weight and passed formed stools without blood, while the anaemia responded to parenteral iron. Sigmoidoscopy before discharge showed that he had greatly improved.
Comment.-The continued activity of the disease while the patient was receiving azathioprine, and the delayed remission, seem to show that the course in this case was unaffected by the antimetabolite.
The accompanying Table presents collected data on the patients' response to therapy.
Discussion
In the present series four out of seven patients with ulcerative colitis started remission on antimetabolites after they had failed to do so on adrenocortical steroid therapy.
Since the relapse encountered in Cases 1 and 5 upon steroid withdrawal at the time antimetabolite therapy was initiated we have made it our practice to continue steroid medication concomitantly with the antimetabolite. However, after beginning the latter therapy smaller doses of steroids were needed in Cases 1, 2, and 4, in which larger doses had been only partially effective or had had no effect. This would parallel the " steroidsparing effect " reported by several authors when " autoimmune" diseases were treated by antimetabolites (Bowen et al., 1966; Clinical Staff Conference, 1963; Mackay et al., 1964) . It is of note that remissions have been achieved in ulcerative colitis by antimetabolites alone (Bowen et al., 1966; Mackay et al., 1966; Swanson and Schwartz, 1967) . This could be of importance in cases where corticosteroids are contraindicated because of complications resulting from their use, or because of underlying disease. Further information on the place of steroid-antimetabolite combinations in the treatment of ulcerative colitis is clearly needed.
In the meantime it seems logical to continue steroid therapy, which is usually tried before antimetabolites, together with the latter medication, and to attempt gradual decrease in dosage of steroids or their complete withdrawal only when remission has begun.
The mechanism of action of antimetabolites in " autoimmune " diseases is not clear. There is poor correlation of clinical response with suppression of various immunological responses, of either the immediate or the delayed type (Bean, 1966b; Swanson and Schwartz, 1967) . The clinical effect might conceivably be due to a nonspecific suppression of the inflammatory response (Page et al., 1962; Demis et al., 1964; Page, 1964; and Hersh et al., 1966) . Either immunosupression or the anti-inflammatory effect may explain the marked decrease in the inflammatory infiltrate observed in rectal biopsies after ulcerative colitis is treated with antimetabolites (Bowen et al., 1966; Bean, 1966a; and Mackay et al., 1966) .
A cause for concern is the suppression of bone marrow by antimetabolites, with leucopenia which can be severe. However, this can be reversed by reduction of dosage or withdrawal of medication (Clinical Staff Conference, 1963 ; Mackay et al., 1966) , as also shown in our cases, and does not usually constitute a hazard. While severe infections do occur in patients with " autoimmune " diseases receiving antimetabolite therapy, their incidence seems to be much lower than in patients after renal transplantation undergoing this treatment (Swanson and Schwartz, 1967) , and the risk seems to be justified in view of the serious nature of the diseases being treated.
Apart from general supportive measures, the means of proved value which are at present at our disposal for the medical management of ulcerative colitis are limited to azosulfidine and adrenocortical steroids. Once these fail the alternative is total colectomy. Any therapeutic modality which may postpone or replace surgery warrants a thorough trial, especially since this mutilating operation is often needed in young patients. (Obviously the indication for surgery here discussed is acute ulcerative colitis, not " surgical" complications or carcinoma.) We therefore feel that further experience should be gained with antimetabolites in the treatment of severe ulcerative colitis; while they are effective in only a proportion of the cases treated, they offer an additional therapeutic modality which carries a relatively minor risk.
There is no indication in the literature that ulcerative colitis is cured by antimetabolites. Their value seems to lie in the induction of remissions, like the previously mentioned agents. However, since each individual relapse of ulcerative colitis can cause severe disability or even death, the control of each episode will have to remain the aim of therapy until such time as a cure is found for this disease.
Addendum
Case 2.-After discontinuing azathioprine therapy in midNovember 1967 this patient's remission was maintained on 20 mg. of prednisone daily for eight months. She then entered hospital in severe relapse, and when she did not respond to large doses of oral prednisone and intravenous A.C.T.H. azathioprine therapy was resumed. Within a few days severe anaemia and leucopenia appeared, and azathioprine was discontinued. The white cell count reached a minimum of 1,200/cu. mm.; high fever and prostration appeared. These responded rapidly to antibiotics and intravenous hydrocortisone, and the patient then agreed to undergo colectomy.
While being prepared for surgery with blood and plasma transfusions (given for anaemia and hypoproteinaemia), and while the white cell count began to rise, she died suddenly-four days after subsidence of the high fever. At necropsy the only finding was universal ulcerative colitis with pseudopolyposis. There was no gross or microscopical evidence of septicaemia.
